These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 31519403)

  • 1. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
    Osibogun O; Ogunmoroti O; Michos ED
    Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease.
    Guan C; Zahid S; Minhas AS; Ouyang P; Vaught A; Baker VL; Michos ED
    Fertil Steril; 2022 May; 117(5):924-935. PubMed ID: 35512976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subclinical cardiovascular disease and polycystic ovary syndrome.
    Gomez JMD; VanHise K; Stachenfeld N; Chan JL; Merz NB; Shufelt C
    Fertil Steril; 2022 May; 117(5):912-923. PubMed ID: 35512975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome.
    Meun C; Gunning MN; Louwers YV; Peters H; Roos-Hesselink J; Roeters van Lennep J; Rueda Ochoa OL; Appelman Y; Lambalk N; Boersma E; Kavousi M; Fauser BC; Laven JS;
    Clin Endocrinol (Oxf); 2020 Feb; 92(2):150-158. PubMed ID: 31638273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
    Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
    J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
    Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic risks in PCOS: a review of the current state of knowledge.
    Kakoly NS; Moran LJ; Teede HJ; Joham AE
    Expert Rev Endocrinol Metab; 2019 Jan; 14(1):23-33. PubMed ID: 30556433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
    Baldani DP; Skrgatic L; Ougouag R; Kasum M
    Gynecol Endocrinol; 2018 Feb; 34(2):87-91. PubMed ID: 28944709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
    Meyer C; McGrath BP; Teede HJ
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5711-6. PubMed ID: 16046590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome.
    Armeni E; Lambrinoudaki I
    Curr Vasc Pharmacol; 2019; 17(6):579-590. PubMed ID: 30156159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovarian syndrome.
    Khan KA; Stas S; Kurukulasuriya LR
    J Cardiometab Syndr; 2006; 1(2):125-30; quiz 131-2. PubMed ID: 17679815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.
    Patel SS; Truong U; King M; Ferland A; Moreau KL; Dorosz J; Hokanson JE; Wang H; Kinney GL; Maahs DM; Eckel RH; Nadeau KJ; Cree-Green M
    Vasc Med; 2017 Apr; 22(2):85-95. PubMed ID: 28095749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease.
    Dubey P; Reddy S; Sharma K; Johnson S; Hardy G; Dwivedi AK
    Curr Cardiol Rep; 2024 Jun; 26(6):483-495. PubMed ID: 38568339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis.
    Woodward A; Klonizakis M; Lahart I; Carter A; Dalton C; Metwally M; Broom D
    Syst Rev; 2019 May; 8(1):116. PubMed ID: 31097035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic syndrome in women: a growing problem for cardiac risk.
    Paul S; Smith L
    J Cardiovasc Nurs; 2005; 20(6):427-32. PubMed ID: 16485627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?
    Carmina E; Lobo RA
    J Womens Health (Larchmt); 2018 Nov; 27(11):1385-1388. PubMed ID: 30199308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemostatic abnormalities and relationships to metabolic and hormonal status in polycystic ovarian syndrome.
    Burchall G; Linden MD; Teede H; Piva TJ
    Trends Cardiovasc Med; 2011 Jan; 21(1):6-14. PubMed ID: 22498014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovary syndrome and metabolic syndrome.
    Ali AT
    Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease risk in first-degree relatives of women with polycystic ovary syndrome.
    Vipin VP; Dabadghao P; Shukla M; Kapoor A; Raghuvanshi AS; Ramesh V
    Fertil Steril; 2016 May; 105(5):1338-1344.e3. PubMed ID: 26852421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.